ASH 2025 Review: Heavy Menstrual Bleeding and Iron Deficiency in Wom…

University of Colorado Division of Hematology

T. Buckner

ASH 2024 Summary: Full or Reduced Dose Apixaban or Rivaroxaban for E…

2024 ASH Annual Meeting Insights Hub

J. Schaefer

Thrombosis in Patients With ITP

Platelet Disorder Support Association (PDSA)

H. Liebman

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Review: New Therapies in ITP

Cleveland Clinic Taussig Cancer Institute

A. Hubben

Updates in Thrombosis and Anticoagulation

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

D. Garcia

Misinformation in ITP

Platelet Disorder Support Association (PDSA)

D. Nugent

AHA 2024 Insights: Rivaroxaban for 18 Months versus 6 Months in Canc…

AHA 2024 Insights

Y. Yamashita

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Thalassemia: Overview of Pathophysiology and Risk for Malignancies

Ali Taher

Current Treatment Guidelines for ITP: Individualized Therapy and Eme…

Irina Murakhovskaya

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

Diagnosis of ITP (Including Differential Diagnosis) and Disease Mana…

Drew Provan

Initial Approach and Considerations for Management of ITP

Nicoletta Machin

Managing Amyloidosis in 2024: Diagnosis and Treatment

Indy Hematology Review

M. Gertz

Thrombophilia Screening: Best Practices and Who Should Be Tested

COR2ED The Heart of Medical Education

S. Middeldorp, J. Connors

Is There a Role for Splenectomy in ITP?

Platelet Disorder Support Association (PDSA)

C. Kessler

Bleeding of Obscure Cause: Stepwise Approach to Diagnosing Bleeding …

Scripps Health

M. Pai

Management of Treatment-Naive ITP Patients

Weill Cornell Medicine Oncology & Hematology

J. Bussel